Skip to main content

Table 1 Patient characteristics

From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

n = 95

Median

Age

77 (48-91) years

Sex

 

Male

49 (51.6%)

Female

46 (48.4%)

Operable

14 (14.7%)

Inoperable

81 (85.3%)

KPS

 

80-100

63 (66.3%)

<70

32 (32.7%)

Clinical follow-up

16.33 (1.13-64.2) months